Thermo Fisher Scientific (TMO) came out with quarterly earnings of $5.79 per share, beating the Zacks Consensus Estimate of $5.5 per share. This compares to earnings of $5.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +5.27%. A quarter ago, it was expected that this maker of scientific instrument and laboratory supplies would post earnings of $5.22 per share when it actually produced earnings of $5.36, delivering a surpri ...

Intuitive Surgical, Inc. (ISRG) came out with quarterly earnings of $2.4 per share, beating the Zacks Consensus Estimate of $1.99 per share. This compares to earnings of $1.84 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +20.60%. A quarter ago, it was expected that this company would post earnings of $1.92 per share when it actually produced earnings of $2.19, delivering a surprise of +14.06%.Over the last four quarters, th ...

Investors with an interest in Medical - Instruments stocks have likely encountered both Hologic (HOLX) and Idexx Laboratories (IDXX) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank is a proven strategy that targets c ...

Hologic (HOLX) closed at $68.50 in the latest trading session, marking a +2.24% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.63%. Elsewhere, the Dow lost 0.65%, while the tech-heavy Nasdaq lost 0.47%. The medical device maker's shares have seen a decrease of 1.76% over the last month, not keeping up with the Medical sector's gain of 3.09% and the S&P 500's gain of 0.92%.The upcoming earnings release of Hologic will be of great interest to investors. The company's earnings report ...

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: SINTX Technologies, Inc. - SINTX Technologies, Inc. currently holds a Momentum Style Score of B and a Zacks Rank of 2 (Buy), indicating a positive outlook for the stock [3][4] - The stock has shown significant price performance, with a 5.08% increase over the past week, contrasting with a 2.74% decline in the Zacks Medical - Instruments industry during the same period [6] - Over the past quarter, SINT's shares have risen by 56.36%, and by 44.78% over the last year, outperforming the S&P 500, which increased by 7.25% and 16.06% respectively [7] Trading Volume and Market Position - SINT's average 20-day trading volume is 106,104 shares, which serves as a baseline for price-to-volume analysis, indicating bullish or bearish trends [8] Earnings Outlook - In the last two months, one earnings estimate for SINT has increased, while none have decreased, leading to a consensus estimate improvement from -$3.44 to -$2.87 for the full year [10] - For the next fiscal year, one estimate has also moved upwards with no downward revisions, suggesting a positive earnings outlook [10] Conclusion - Considering the positive momentum indicators and earnings outlook, SINTX Technologies, Inc. is positioned as a promising investment opportunity with a Momentum Score of B and a Zacks Rank of 2 (Buy) [12]

Core Insights - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] - The Zacks Momentum Style Score helps investors identify stocks with strong momentum, addressing the challenges of defining momentum [2] Company Overview: Lucid Diagnostics Inc. (LUCD) - Lucid Diagnostics Inc. currently holds a Momentum Style Score of B, indicating potential for solid momentum [3] - The company has a Zacks Rank of 2 (Buy), suggesting it is positioned for outperformance in the market [4] Performance Metrics - Over the past week, LUCD shares increased by 10.58%, while the Zacks Medical - Instruments industry declined by 2.74% [6] - In a longer timeframe, LUCD's monthly price change is 17.76%, significantly outperforming the industry's 0.67% [6] - Over the past quarter, LUCD shares rose by 12.5%, and over the last year, they gained 55.56%, compared to the S&P 500's increases of 7.25% and 16.06%, respectively [7] Trading Volume - LUCD's average 20-day trading volume is 1,341,620 shares, indicating a bullish sign with rising stock prices and above-average volume [8] Earnings Outlook - Recent earnings estimate revisions show one upward revision for the full year, raising the consensus estimate from -$0.41 to -$0.35 [10] - For the next fiscal year, one estimate has moved upwards with no downward revisions, indicating positive sentiment [10] Conclusion - Considering the performance metrics and earnings outlook, LUCD is positioned as a 2 (Buy) stock with a Momentum Score of B, making it a potential candidate for near-term investment [12]

Pacific Biosciences of California (PACB) ended the recent trading session at $1.59, demonstrating a -1.85% change from the preceding day's closing price. This change lagged the S&P 500's 0.16% loss on the day. Elsewhere, the Dow saw an upswing of 0.44%, while the tech-heavy Nasdaq depreciated by 0.76%. Prior to today's trading, shares of the maker of genetic analysis technology had gained 35% outpaced the Medical sector's gain of 1.54% and the S&P 500's gain of 1.14%.The upcoming earnings release of Pacific ...

Core Viewpoint - Hologic (HOLX) has been trending in stock searches, with a recent performance of +2.7% over the past month, outperforming the S&P 500's +1.1% and the Zacks Medical - Instruments industry's -6.2% [1] Earnings Estimates - For the current quarter, Hologic is expected to report earnings of $1.10 per share, reflecting an increase of +8.9% year-over-year, although the Zacks Consensus Estimate has decreased by -0.3% in the last 30 days [4] - The consensus earnings estimate for the current fiscal year is $4.24, indicating a +3.9% change from the previous year, with a slight decrease of -0.1% over the last month [4] - For the next fiscal year, the consensus estimate is $4.48, showing a +5.6% increase from the prior year, with no change in the estimate over the past month [5] Revenue Growth - Hologic's consensus sales estimate for the current quarter is $1.03 billion, representing a year-over-year increase of +4.7% [10] - The sales estimates for the current and next fiscal years are $4.08 billion and $4.26 billion, indicating changes of +1.4% and +4.3%, respectively [10] Recent Performance and Surprise History - In the last reported quarter, Hologic achieved revenues of $1.02 billion, a +1.2% increase year-over-year, and an EPS of $1.08, compared to $1.06 a year ago [11] - The company surpassed consensus EPS estimates three times and revenue estimates three times over the last four quarters [12] Valuation - Hologic is graded B in the Zacks Value Style Score, suggesting it is trading at a discount compared to its peers [16]

Pacific Biosciences of California (PACB) ended the recent trading session at $1.52, demonstrating a +2.01% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.37%. Elsewhere, the Dow saw a downswing of 0.14%, while the tech-heavy Nasdaq appreciated by 0.71%. Prior to today's trading, shares of the maker of genetic analysis technology had gained 17.32% outpaced the Medical sector's gain of 5.9% and the S&P 500's gain of 4.26%.Analysts and investors al ...

Investors in Masimo Corporation (MASI) need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 17, 2025 $70.00 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could al ...